Viral vectors and their use in therapeutic methods

• US 8,470,577 B2
• Filed: 03/11/2010
• Issued: 06/25/2013
• Est. Priority Date: 03/27/2001
• Status: Expired due to Term

• Current Assignee: Catherex, Inc. (Amgen Inc.), Georgetown University, The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: Catherex, Inc. (Amgen Inc.), Georgetown University, The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Johnson, Paul, Martuza, Robert L., Rabkin, Samuel D., Todo, Tomoki
• Primary Examiner(s): Mosher, Mary E.
• Assistant Examiner(s): HILL, MYRON G
• Application Number:
  US12/721,599
• Publication Number:
  US 20110070262A1
• Time in Patent Office: 1,202 Days
• Field of Search: None
• US Class Current: 435/235.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/585 wherein the target is cancer
• CPC Class Codes: A61K 35/763 Herpes virus
• CPC Class Codes: A61K 35/768 Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
• CPC Class Codes: A61K 38/162 from virus
• CPC Class Codes: A61K 39/245 Herpetoviridae, e.g. herpes simplex virus
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/16632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/16634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/16643 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/16662 : by genetic engineering
• CPC Class Codes: C12N 2710/16671 : Demonstrated in vivo effect
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Claims

1. A herpes simplex virus-1 (HSV-1) comprising an inactivating mutation in the ICP47 locus of the virus, wherein said mutation occurs between the BstEII site and the EcoNI site of the BamH1 fragment encompassing the ICP47 region, and said mutation places US11 under control of the ICP47 immediate-early promoter, said virus further comprising one or more additional mutations selected from the group consisting of an inactivating mutation in the γ

34.5 neurovirulence determination locus and an inactivating mutation in the ICP6 locus.

2. A herpes simplex virus-1 (HSV-1) comprising an inactivating mutation in the ICP47 locus of the virus, wherein said mutation occurs between the BstEII site and the EcoNI site of the BamH1 fragment encompassing the ICP47 region, and said mutation places US11 under control of the ICP47 immediate-early promoter, said virus further comprising an inactivating mutation in the γ

34.5 neurovirulence locus of said virus and an inactivating mutation in the ICP6 locus of said virus.

3. A pharmaceutical composition comprising the virus of claim 2 and a pharmaceutically acceptable carrier, adjuvant, or diluent.

4. A herpes simplex virus-1 (HSV-1) comprising a deletion, wherein said deletion comprises the region between the BstEII site and the EcoNI site of the BamH1 fragment encompassing the ICP47 region and the deletion places US11 under control of the ICP47 immediate-early promoter, said virus further comprising one or more additional mutations selected from the group consisting of an inactivating mutation in the γ

34.5 neurovirulence determination locus and an inactivating mutation in the ICP6 locus.

5. A pharmaceutical composition comprising the virus of claim 4 and a pharmaceutically acceptable carrier, adjuvant, or diluent.